Novo Nordisk

ESPEROCT

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Novo Nordisk

Esperoct HCPCS:

J7204

HCPCS Code Descriptor:

Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu

Category:

J Code

Esperoct NDCs:

00169-8100-01, 00169-8500-01, 00169-8200-01, 00169-8300-01, 00169-8150-01

Primary Type:

Hematology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Esperoct CPT Codes:

Potential CPT administration codes for Esperoct can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Esperoct:

ESPEROCT is a Hematology drug manufactured by Novo Nordisk and administered via the Intravenous route of administration. The J Code: J7204 is aligned to the drug ESPEROCT.

ACCESS PRICING AND MORE BY REGISTERING

J7204 Added Date:

July 1, 2020

J7204 Effective Date:

July 1, 2020

J7204 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Esperoct billing and coding information.
Esperoct patient assistance information can be found through Novo Nordisk’s NovoCare at the URL: https://www.mynovosecure.com/resources.html
ESPEROCT prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for ESPEROCT. Please check back in a few weeks.